Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

DelMar Pharmaceuticals Amends Glioblastoma Trial

August 19, 2014 11:49 am | News | Comments

DelMar Pharmaceuticals Inc. announced a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration and that a new cohort of a new 50mg/m2 has been opened at three clinical trial sites in the United States. Read more...

TOPICS:

Eisai, Zeria Collaborate on Proton Pump Inhibitor in Japan

August 19, 2014 11:44 am | News | Comments

Eisai Co. Ltd. and Zeria Pharmaceutical Co. Ltd. announced that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai, which shows promise as a best-in-class treatment. Read more...

TOPICS:

FDA Tentatively Approves Lilly, BI Insulin Glargine

August 19, 2014 11:37 am | News | Comments

The U.S. Food and Drug Administration granted tentative approval for Basaglar (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Read more...

TOPICS:
Advertisement

AstraZeneca Posts Positive Antibiotic Combo Results

August 19, 2014 11:30 am | News | Comments

AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase 3 studies investigating the potential of the antibiotic ceftazidime-avibactam as a treatment for hospitalized adult patients with complicated intra-abdominal infections. Read more...

TOPICS:

Unlocking the Power of Big Data in R&D, Part Two

August 19, 2014 11:23 am | by Sharon Benzeno, PhD, MBA, Senior Director, Business Development Bioinformatics, Elsevier | Articles | Comments

Big data is one of the hottest topics in R&D as its potential to accelerate successful drug development becomes more widely recognized. Part 2 of this two-part article analyses the new data-driven decision-making approaches make a difference to life science R&D. Read more...

TOPICS:

Breaking News: All Missing Ebola Patients Are Back

August 19, 2014 10:16 am | by Jonathan Paye-Layleh, John Heilprin, Associated Press | News | Comments

All the people who were being screened for Ebola when they fled a health center during looting are now back in a hospital, a Liberian official said Tuesda, but it is still not clear where the stolen bloody sheets and mattresses are. Read more...

TOPICS:

Small Molecules, Stem Cells Can Improve Hearing

August 18, 2014 3:14 pm | by Cynthia Fox, Science Editor | Articles | Comments

A scientist has found that a compound, LY-411575, can restore 20% of hearing in deaf mice, or ten decibels. Since electroacoustic hearing aids, at best, improve hearing by five decibels, there is a “good chance” the work will lead to help for deafened patients.

TOPICS:

HPV Vaccine Remains Effective After Eight Years, Study Says

August 18, 2014 2:39 pm | News | Comments

A new study examined whether the HPV vaccine remains effective 8 years after initial vaccination. The study followed boys and girls who were vaccinated with the HPV vaccine between the ages of 9 and 15. Read more...          

TOPICS:
Advertisement

Ruxolitinib Restores Hair in Alopecia Areata

August 18, 2014 2:28 pm | News | Comments

Researchers have identified the immune cells responsible for destroying hair follicles in people with alopecia areata, a common autoimmune disease that causes hair loss, and have tested an FDA-approved drug that eliminated these immune cells and restored hair growth in a small number of patients. Read more...

TOPICS:

FDA Approves Biogen's MS Drug Plegridy

August 18, 2014 2:06 pm | News | Comments

Biogen Idec said Friday that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis. Read more...                        

TOPICS:

CDC Scientist Kept Quiet About Flu Blunder

August 18, 2014 2:02 pm | by Mike Stobbe, AP Medical Writer | News | Comments

A government scientist kept silent about a potentially dangerous lab blunder and revealed it only after workers in another lab noticed something fishy, according to an internal investigation. Read more...              

TOPICS:

Allergan Names New CFO Amid Valeant Struggle

August 18, 2014 1:31 pm | News | Comments

Botox maker Allergan, which is fighting a hostile takeover bid from Valeant Pharmaceuticals, has named longtime executive Jim Hindman its new chief financial officer. Read more...                    

TOPICS:

UK Agrees to Re-Review Prostate Cancer Drug

August 18, 2014 11:16 am | News | Comments

Ferring Pharmaceuticals confirmed that, following an oral hearing in London, the panel upheld Ferring's appeal against the National Institute for Health and Care Excellence's final appraisal determination for the use of Firmagon as an option for treating advanced hormone-dependent prostate cancer. Read more...

TOPICS:

Daiichi Sankyo Kicks Off Etanercept Biosimilar Trial

August 18, 2014 11:11 am | News | Comments

Daiichi Sankyo Co. Ltd., in collaboration with the U.S. company Coherus BioSciences Inc., announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar, in rheumatoid arthritis (the RApsody trial) in Japan. Read more...

TOPICS:

Pfizer Submits NDA for Breast Cancer Drug

August 18, 2014 11:04 am | News | Comments

Pfizer Inc. announced it has completed the submission of a New Drug Application to the U.S. Food and Drug Administration for palbociclib in combination with letrozole for the treatment of postmenopausal women with ER+/HER2- breast cancer who have not received previous systemic treatment for advanced disease. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading